Eli Lilly disclosed in an SEC filing that Nobel laureate Carolyn Bertozzi will rejoin its board on Dec. 8. Bertozzi, awarded the 2022 Nobel Prize in Chemistry, brings expertise in glycobiology and translational biochemistry that Lilly said will inform its R&D and governance oversight. The appointment signals Lilly’s push to reinforce scientific leadership at the board level as the company advances oncology and molecular medicine programs. Bertozzi’s return is notable given her profile in academia and biotech, and it may influence Lilly’s strategic engagement with early-stage science and platform technologies.